Surveying antigen-specific CDR3 sequences provides deeper insight into T-cell population dynamics in response to cancer, infection, or autoimmune disease. Bulk next- generation sequencing (NGS) is capable of providing an in-depth characterization of lymphocyte populations, such as tumor infiltrating lymphocytes, through measurement of diversity and clonality using CDR3 TCRβ sequences.1 Furthermore, NGS allows for resolution of nucleotide CDR3 sequences of TCRβ rearrangements enabling insight into T-cell receptor (TCR) convergence of the immune repertoire. In Immune Checkpoint therapy, dynamic changes in the T-cell repertoire shortly after initiation of treatment could inform response and biomarker development through identification of a peripheral blood early immune-signature allowing for more effective stratification.2 Recently, TCR repertoire signatures were shown to be associated with COVID-19 disease severity and could potentially be used to enhance our understanding of patient prognosis.3 Inquire with us to learn more about our TCR immune repertoire sequencing capabilities.
Highlights:
Testing Services | |||
---|---|---|---|
Assay Format | Sample Type | DNA Input Requirements | Applications |
Clonality Testing | Whole blood PBMC FFPE Fresh Frozen |
0.05 – 2 µg | Examine TCR clonality and dominant TCR clonotypes |
High Sensitivity | Whole blood PBMC |
0.5 – 24 µg | Examine rare TCR clonotypes, sensitivity is input dependent |
Assay Specifications | |
---|---|
Assay Method | Oncomine TCR βeta-SR Assay (DNA) |
Gene Targets | T-cell receptor β chains, CDR3 region |
Platform | Ion GeneStudio S5 System |
Sample Type | Whole Blood, PBMC, FFPE, Fresh Frozen, DNA |
Storage and Shipping |
Whole Blood (DNA) (Stored at -80°C, shipped frozen on dry ice) |
Deliverables | TCR clone frequency and abundance CDR3 TRB sequences (nucleic acid and amino acid sequences, productive/unproductive rearrangements) V-J segment utilization Shannon Diversity/Evenness Convergent TCR Frequency |
1 Sanz-Pamplona R, et al., 2020, PLoS Med 17(9): e1003292. https://doi.org/10.1371/journal.pmed.1003292
2 Valpione Et al., 2020, Nat Cancer 1(2): 210–221. https://doi:10.1038/s43018-019-0022-x
3 Schultheiß et al., 2020, Immunity 53, 442–455. https://doi:10.1016/j.immuni.2020.06.024
*Sensitivity is input and sample type dependent. Please inquire with us to discuss recommendations for optimal performance.